Photo taken from Vivek Subbiah/LinkedIn
Oct 1, 2023, 16:07
Vivek Subbiah: Fantastic keynote lecture on “The FDA perspective on early phase pre-market dose optimization” by the amazing Dr. Paul Kluetz.
Vivek Subbiah shared on X/Twitter:
“Fantastic keynote lecture on “The FDA perspective on early phase pre-market dose optimization” by the amazing Dr. Paul Kluetz.
- OCE’s Project Optimus
- Dose optimization in early phase drug development
- Patient reported outcomes and patient generated data
- Master Protocols
- Decentralized elements
Wow! Every slide and every bullet point resonates with early phase investigators. Standing ovation.”
Source: Vivek Subbiah/Twitter
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12